Actively Recruiting
The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study
Led by Ningbo Medical Center Lihuili Hospital · Updated on 2024-01-03
30
Participants Needed
1
Research Sites
146 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn about Drug loaded microspheres for bronchial artery chemoembolization (DEB-BACE) combined with anlotinib and adebelimumab in patients with advanced NSCLC after second-line treatment. The main question it aims to answer is: The efficacy and safety of Drug Loading Beads Bronchial Arterial Chemoembolization (DEB-BACE) combined with Anlotinib and Adebelimumab in the third line treatment of advanced NSCLC. Participants will receive DEB-BACE treatment, rest for 1 week and then undergo 1 cycle of treatment with combination of Anlotinib and Adebelimumab. With a maximum of 4 DEB-BACE treatments depending on the therapeutic effect, followed by continued treatment with Anlotinib and Adebelimumab.
CONDITIONS
Official Title
The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 18 years, any gender
- Diagnosed with Non-Small Cell Lung Cancer by pathology
- Cancer stage III or IV according to TNM staging
- Failure of second-line treatment as defined by CSCO guidelines
- ECOG performance status score of 2 or less
- Estimated life expectancy more than 3 months
- Signed informed consent form
You will not qualify if you...
- Previous interventional therapy including iodine particle implantation, ablation, or BACE treatment
- Prior PD-L1 inhibitor immunotherapy during first or second line treatment
- Current other untreated malignant tumors
- White blood cell count below 3 x 10^9/L or neutrophil count below 1.5 x 10^9/L
- Neutrophil to lymphocyte ratio equal to or above 3
- Platelet count below 50 x 10^9/L
- Hemoglobin concentration below 90 g/L
- Liver or kidney dysfunction with creatinine above 176.8 µmol/L
- Elevated AST or ALT greater than twice the normal upper limit
- Central squamous cell carcinoma with cavity features
- Uncorrectable coagulation problems or active massive bleeding
- Active infections requiring antibiotic treatment
- Uncontrolled hypertension, diabetes, or cardiovascular diseases with obvious symptoms
- Allergy to contrast agents
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kaitai Liu
Ningbo, Zhejiang, China, 315040
Actively Recruiting
Research Team
K
kaitai liu, doctor
CONTACT
J
jingtao tong, master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here